Bruker Corporation $BRKR Shares Sold by Bessemer Group Inc.

Bessemer Group Inc. reduced its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 68.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,740 shares of the medical research company’s stock after selling 14,606 shares during the quarter. Bessemer Group Inc.’s holdings in Bruker were worth $244,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the company. Los Angeles Capital Management LLC purchased a new position in Bruker during the 4th quarter valued at about $26,000. Allworth Financial LP boosted its stake in Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after buying an additional 257 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after acquiring an additional 479 shares during the last quarter. Summit Securities Group LLC purchased a new stake in shares of Bruker during the 4th quarter valued at $50,000. Finally, Covestor Ltd grew its position in Bruker by 304.6% during the fourth quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 1,066 shares during the period. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Stock Performance

Shares of BRKR opened at $60.45 on Monday. The stock has a market capitalization of $9.20 billion, a P/E ratio of -251.88, a P/E/G ratio of 1.94 and a beta of 1.29. Bruker Corporation has a 12-month low of $28.53 and a 12-month high of $64.54. The firm’s 50 day moving average is $56.32 and its 200-day moving average is $46.29. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. The company had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The company’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts anticipate that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend was Monday, June 22nd. Bruker’s dividend payout ratio is currently -83.33%.

Wall Street Analysts Forecast Growth

BRKR has been the subject of several recent research reports. TD Cowen reissued a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. UBS Group set a $60.00 target price on Bruker in a research report on Wednesday, June 24th. Leerink Partners increased their price target on shares of Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Finally, Wolfe Research initiated coverage on Bruker in a research note on Monday, June 1st. They issued a “peer perform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bruker has an average rating of “Hold” and a consensus price target of $56.79.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.